Valeo Financial Advisors LLC Sells 1,853 Shares of Danaher Corporation (NYSE:DHR)

Valeo Financial Advisors LLC decreased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 13.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,675 shares of the conglomerate's stock after selling 1,853 shares during the period. Valeo Financial Advisors LLC's holdings in Danaher were worth $2,393,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Stratos Wealth Advisors LLC grew its holdings in shares of Danaher by 13.1% during the 1st quarter. Stratos Wealth Advisors LLC now owns 15,707 shares of the conglomerate's stock worth $3,220,000 after acquiring an additional 1,817 shares during the period. Harbour Investment Management LLC grew its stake in shares of Danaher by 1.2% in the 1st quarter. Harbour Investment Management LLC now owns 10,952 shares of the conglomerate's stock worth $2,249,000 after buying an additional 135 shares during the last quarter. Interchange Capital Partners LLC boosted its stake in Danaher by 8.5% during the 1st quarter. Interchange Capital Partners LLC now owns 1,939 shares of the conglomerate's stock valued at $397,000 after purchasing an additional 152 shares during the last quarter. Financial Counselors Inc. boosted its stake in Danaher by 3.9% during the 1st quarter. Financial Counselors Inc. now owns 117,434 shares of the conglomerate's stock valued at $24,074,000 after purchasing an additional 4,378 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Danaher by 14.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 1,261,196 shares of the conglomerate's stock valued at $258,545,000 after purchasing an additional 155,537 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Danaher Trading Down 0.3%

DHR traded down $0.71 on Friday, hitting $204.80. The company had a trading volume of 2,369,010 shares, compared to its average volume of 3,501,538. The company has a market cap of $146.57 billion, a PE ratio of 39.77, a PEG ratio of 2.82 and a beta of 0.77. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The business's fifty day simple moving average is $195.94 and its 200 day simple moving average is $206.65.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Activity at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on DHR. Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target on the stock in a report on Friday, March 14th. UBS Group cut their price target on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI cut their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday. Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, April 23rd. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research note on Friday. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $248.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.